Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

NCT02914184 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02914184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02914184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
October 27, 2016
Completion date
November 26, 2018
Enrollment
1,612 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

infections, rotavirus, rotavirus vaccines